Dr Reddy’s announces closure of the transaction to divest Zembrace SymTouch and Tosymra to…
The transaction, including the applicable waiting period, was completed under the Hart-Scott-Rodino Antitrust Improvements Act of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Promius Pharma
Promius Pharma launches Sernivo (betamethasone dipropionate) spray
It is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older
Dr Reddy’s Labs has…
DRL’s migraine drug ZEMBRACE SymTouch launched in US
It is available in a box containing 4 autoinjectors
Promius Pharma receives FDA approval for Sernivo spray
Sernivo spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older
Sales rep files sexual harassment claims against DRL, Promius Pharma
The case was filed on July 31, 2015 and the nature of the suit is civil rights-employment A woman sales representative from…
DRL Laboratories signs commercialisation deal with Hatchtech
DRL will pay Hatchtech an upfront amount of $10 million, up to $ 50 million
DRL, Promius Pharma files NDAs with US FDA
Dr Reddy’s Laboratories and its subsidiary, Promius Pharma announced the filing of three 505(b)(2) New Drug Applications (NDAs)…
DRL and its subsidiary Promius Pharma files three NDAs with US FDA
The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr Reddy’s Proprietary Products group